名称 | Brusatol |
描述 | Brusatol (NSC-172924) is a natural product isolated from the Brucea javanica plant. It inhibits Nrf2. |
细胞实验 | CT-26 cells in logarithmic growth are seeded onto a 96-well plate at a density of 4×10^3 cells/well. After 24 h of incubation at 37°C, fresh medium containing a series of concentrations of Brusatol (0.05, 0.15, 0.45, 1.35, 4.05 and 12.15 μg/mL) and CDDP (0.05, 0.15, 0.45, 1.35, 4.05 and 12.15 μg/mL) is added at 100 μL/well; each concentration is used to treat six replicate wells. After 48 h of incubation at 37°C, the cells are further incubated with MTT (10 mg/mL) at 37°C for 4 h. The supernatant is then removed and the precipitate is dissolved with 100 μL DMSO. Absorbance is measured using a microplate reader at a wavelength of 490 nm. Cytotoxicity is expressed as the concentration of Brusatol and CDDP that inhibit cell growth by 50% (IC50 value). The inhibitory rate is calculated. The possible synergistic effect of Brusatol combined with CDDP is investigated by exposing CT-26 cells to various concentrations of each agent alone or in combination for 48 h [2]. |
动物实验 | Athymic nude mice are used. Mice 4-6 wk old are injected with A549 cells. Once the tumors reached 80 mm3 (for the two times five-time Cisplatin treatment regimen) or 280 mm3 (for the single five-time Cisplatin treatment regime), mice are randomly allocated into four groups and treated i.p. with DMSO, Cisplatin (2 mg/kg), Brusatol (2 mg/kg), or in combination every other day for a total of five times. After the initial five-time Cisplatin treatment regimen, treatment stops for 1 wk to allow mice to recover before the second five-time Cisplatin treatment regimen is repeated [3]. |
体外活性 | Brusatol 通过一种不依赖于 Keap1、蛋白酶体和自噬蛋白降解系统的机制,引发 Nrf2 的消耗。在小鼠 Hepa-1c1c7 肝癌细胞中,Brusatol 通过一种转录后机制迅速且短暂地引起 Nrf2 蛋白的消耗。Brusatol 也能抑制新鲜分离的原代人肝细胞中的 Nrf2 [1]。CT-26 细胞分别单独或联合应用不同浓度的 Brusatol(0.05、0.15、0.45、1.35、4.05 和 12.15 μg/mL)和 CDDP(0.05、0.15、0.45、1.35、4.05 和 12.15 μg/mL)处理 48 小时。经 Brusatol 和 CDDP 处理 48 小时后,CT-26 细胞的存活率呈剂量依赖性降低,其 IC50 值分别为 0.27±0.01 和 1.44±0.22 μg/mL。当 Brusatol 与 CDDP 以 1:1 的恒定浓度比联合应用时,细胞生长抑制明显增强,合用治疗的 IC50 值为 0.19±0.02 μg/mL [2]。 |
体内活性 | 裸鼠被注射A549细胞以诱导肿瘤生长,随后进行一次每千克体重2 mg的Brusatol腹腔注射。在注射后24小时或48小时,将肿瘤组织分离出来。发现Nrf2蛋白水平在注射后24小时或48小时显著降低,表明Brusatol能够达到肿瘤组织并抑制Nrf2途径。在第一次实验中,一旦肿瘤体积达到平均230 mm3,将DMSO、Brusatol(每千克体重2 mg)、Cisplatin(每千克体重2 mg)或Cisplatin(每千克体重2 mg)与Brusatol(每千克体重2 mg)联合治疗通过腹腔注射,每隔一天一次,共五次。Cisplatin或Brusatol单独使用未能显著抑制肿瘤生长,而在联合治疗组中,肿瘤体积显著减小[3]。 |
存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | H2O : Insoluble DMSO : 90 mg/mL (172.9 mM)
|
关键字 | Nrf2 | oxygen | CT-26 | defense | stress | Keap1-Nrf2 | Brusatol | chemosensitization | Toxicity | NSC-172924 | species | radicals | reactive | Chemical | response | cisplatin | synergistic effect | Hepatocyte | Keap1 | antioxidant | Cell | Free | Inhibitor | inhibit | NSC172924 | Apoptosis |
相关产品 | L-Cystine | Coenzyme Q10 | L-Glutamic acid | L-Glutamic acid monosodium salt | Resveratrol | Artemisinin | Curcumin | α-Vitamin E | Butylated hydroxytoluene | Sorafenib | TBHQ | Ammonium iron(III) citrate |
相关库 | 经典已知活性库 | 抗癌活性化合物库 | 植物来源化合物库 | 已知活性化合物库 | 抗癌天然产物库 | 天然产物库 | 中药单体化合物库 | 中药抗炎分子库 | 萜类天然产物库 | 抗寄生虫天然产物库 |